These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 35714328)

  • 1. Vaccination After SARS-CoV-2 Infection Increased Antibody Avidity Against the Omicron Variant Compared to Vaccination Alone.
    LeMaster C; Geanes ES; Fraley ER; Selvarangan R; Bradley T
    J Infect Dis; 2022 Nov; 226(10):1712-1716. PubMed ID: 35714328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
    Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
    Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
    Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
    EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of mRNA vaccination-elicited RBD-specific memory B cells reveals strong but incomplete immune escape of the SARS-CoV-2 Omicron variant.
    Sokal A; Broketa M; Barba-Spaeth G; Meola A; Fernández I; Fourati S; Azzaoui I; de La Selle A; Vandenberghe A; Roeser A; Bouvier-Alias M; Crickx E; Languille L; Michel M; Godeau B; Gallien S; Melica G; Nguyen Y; Zarrouk V; Canoui-Poitrine F; Noizat-Pirenne F; Megret J; Pawlotsky JM; Fillatreau S; Simon-Lorière E; Weill JC; Reynaud CA; Rey FA; Bruhns P; Chappert P; Mahévas M
    Immunity; 2022 Jun; 55(6):1096-1104.e4. PubMed ID: 35483354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
    Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
    mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Neutralizing Antibody Response Against SARS-CoV-2 Variants After 2 to 3 Doses of the BNT162b2 mRNA COVID-19 Vaccine.
    Furukawa K; Tjan LH; Kurahashi Y; Sutandhio S; Nishimura M; Arii J; Mori Y
    JAMA Netw Open; 2022 May; 5(5):e2210780. PubMed ID: 35532938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of SARS-CoV-2 Antibody Responses up to 9 Months Post-Vaccination in Individuals with Previous SARS-CoV-2 Infection Receiving Inactivated Vaccines.
    Wang J; Huang L; Guo N; Yao YP; Zhang C; Xu R; Jiao YM; Li YQ; Song YR; Wang FS; Fan X
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infection-mediated immune response in SARS-CoV-2 breakthrough infection and implications for next-generation COVID-19 vaccine development.
    Miyamoto S; Suzuki T
    Vaccine; 2024 Feb; 42(6):1401-1406. PubMed ID: 38310015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy.
    Priddey A; Chen-Xu MXH; Cooper DJ; MacMillan S; Meisl G; Xu CK; Hosmillo M; Goodfellow IG; Kollyfas R; Doffinger R; Bradley JR; Mohorianu II; Jones R; Knowles TPJ; Smith R; Kosmoliaptsis V
    Front Immunol; 2023; 14():1296148. PubMed ID: 38259440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease severity and efficacy of homologous vaccination among patients infected with SARS-CoV-2 Delta or Omicron VOCs, compared to unvaccinated using main biomarkers.
    Ali AM; Tofiq AM; Rostam HM; Ali KM; Tawfeeq HM
    J Med Virol; 2022 Dec; 94(12):5867-5876. PubMed ID: 36029103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Previous COVID-19 Vaccination on Humoral Immunity 3 Months after SARS-CoV-2 Omicron Infection and Booster Effect of a Fourth COVID-19 Vaccination 2 Months after SARS-CoV-2 Omicron Infection.
    Kim J; Seo H; Kim HW; Kim D; Kwon HJ; Kim YK
    Viruses; 2022 Nov; 14(11):. PubMed ID: 36366556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retained avidity despite reduced cross-binding and cross-neutralizing antibody levels to Omicron after SARS-COV-2 wild-type infection or mRNA double vaccination.
    Harthaller T; Falkensammer B; Bante D; Huber M; Schmitt M; Benainouna H; Rössler A; Fleischer V; von Laer D; Kimpel J; Würzner R; Borena W
    Front Immunol; 2023; 14():1196988. PubMed ID: 37545492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination.
    Bellusci L; Grubbs G; Zahra FT; Forgacs D; Golding H; Ross TM; Khurana S
    Nat Commun; 2022 Aug; 13(1):4617. PubMed ID: 35941152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiplexed evaluation of immunity against SARS-CoV-2 variants using surface enhanced fluorescence from a nanostructured plasmonic chip.
    Hu R; Yang Y; Liu Y; Liao T; Liu Y; Tang J; Wang G; Wang G; Liang Y; Yuan J; Zhang B
    J Nanobiotechnology; 2022 Dec; 20(1):533. PubMed ID: 36522786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of Bivalent Omicron-Containing Booster Vaccines against SARS-CoV-2 Omicron Variant among Individuals with and without Prior SARS-CoV-2 Infection.
    Widyasari K; Jang J; Kang T; Kim S
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Waning Neutralizing Antibody Responses Against the Omicron Variant 6 Months After Natural Severe Acute Respiratory Syndrome Coronavirus 2 Infection (With or Without Subsequent Coronavirus Disease 2019 [COVID-19] Vaccination) Versus 2-Dose COVID-19 Vaccination.
    Lim SY; Park S; Kim JY; Kim S; Jee Y; Kim SH
    Clin Infect Dis; 2022 Dec; 75(12):2243-2246. PubMed ID: 35686300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of Immune Response After COVID-19 Booster Vaccination and Association With COVID-19 Omicron Infection.
    Gilboa M; Regev-Yochay G; Mandelboim M; Indenbaum V; Asraf K; Fluss R; Amit S; Mendelson E; Doolman R; Afek A; Freedman LS; Kreiss Y; Lustig Y
    JAMA Netw Open; 2022 Sep; 5(9):e2231778. PubMed ID: 36107426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.